Article

Discovery and Preclinical Validation of a Clinically Optimized Mitochondrial Complex I Modulator for Alzheimer’s Disease

2026-04-14

Abstract excerpt

Alzheimer’s disease (AD) is characterized by diminished capacity to mount adaptive cellular stress responses required to maintain energy homeostasis and proteostasis. An emerging therapeutic strategy is to restore adaptive stress responses by inducing mild energetic stress through inhibition of mitochondrial complex I (mtCI). However, pharmacological inhibition of the respiratory chain has remained challenging, as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e790ec78-2e03-5276-a875-26eec43e3397
DOI: 10.64898/2026.04.10.717554

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery and Preclinical Validation of a Clinically Optimized Mitochondrial Complex I Modulator for Alzheimer’s DiseaseDOI 10.64898/2026.04.10.717554Read

Partial inhibition of mitochondrial complex I attenuates neurodegeneration and restores energy homeostasis and synaptic function in a symptomatic Alzheimer’s mouse modelSemantic proximity Read

Exploring the Mechanisms and Therapeutic Approaches of Mitochondrial Dysfunction in Alzheimer’s Disease: An Educational Literature ReviewSemantic proximity Read

Mitochondrial Complex I Modulator Restores Network Resilience in Advanced Alzheimer’s Disease Through Metabolic ReprogrammingSemantic proximity Read

Mitochondrial complex I deficiency induces Alzheimer's disease–like signatures that are reversible by targeted therapySemantic proximity Read

New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer’s diseaseSemantic proximity Read

Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the PotentialSemantic proximity Read

Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial OpportunitiesSemantic proximity Read

Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide ameliorates AD-like pathology in the APP/PS1 mouse model.Semantic proximity Read

Hampered AMPK-ULK1 cascade in Alzheimer’s disease (AD) instigates mitochondria dysfunctions and AD-related alterations that are alleviated by metforminSemantic proximity Read

Curcumin in Alzheimer’s Disease: From Mechanistic Insights to Translational Challenges and Emerging Curcuminoid StrategiesSemantic proximity Read

Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s DiseaseSemantic proximity Read

Inhibition of the ER stress IRE1α inflammatory pathway protects against cell death in mitochondrial complex I mutant cells.Semantic proximity Read